$PLUS

Marion Elaine D sold $268K of PLUS (indirect holdings)

Marion Elaine D (CHIEF FINANCIAL OFFICER) sold 2,818 indirectly-held shares of EPLUS INC (PLUS) at an average of $95.22 ($95.22–$95.25, $0.27M total) across 2 trades on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marion Elaine D
Published Jul 31, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PLUS
Neutral
high confidence
Mentioned
$PLUS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, pricing range, and that the CFO ended with 0 shares; there is no accompanying company guidance or event.

02

Market read

Traders may note the CFO’s scheduled selling, but the 10b5-1 framing and lack of other catalysts suggest minimal incremental trading edge.

03

What to watch

Indirect holdings and the CFO’s post-sale position (0 shares) can be mechanically driven by prior grants, taxes, or diversification, reducing signal strength.

Relevance 3/10Novelty 2/10Timing: filed 2026-07-31 after-hours; trades dated 2026-07-29

Background

The article is a SEC Form 4 insider transaction disclosure for EPLUS Inc (PLUS) by its CFO, reported as an indirect holding sale under a 10b5-1 plan.

Company-level read

Ticker impact

$PLUSNeutralHigh confidence
Context

EPLUS CFO Marion Elaine D sold $268,336 of PLUS shares via an open-market sale under a pre-arranged 10b5-1 plan, leaving 0 shares.

Expected impact

Likely limited near-term impact; treat as informational rather than a fundamental reset.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan and no accompanying guidance, deal, or regulatory action.

Market effects

No clear sector read-through; this is company-specific insider activity without new business information.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • PLUS

    EPLUS Inc, issuer of the Form 4 insider transaction disclosed in the article.

  • Marion Elaine D

    Chief Financial Officer of EPLUS Inc, reported as the insider selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDWMedAI 8/10

Q2 Earnings Outperformers: CDW (NASDAQ:CDW) And The Rest Of The IT Distribution & Solutions Stocks

CDW, ePlus, TD SYNNEX, and ScanSource reported Q2 earnings. CDW (-6%) and ePlus (-10.5%) saw stock declines, while ScanSource (+5.5%) rose. TD SYNNEX (-10.5%) reported strong revenue growth but also fell. ePlus reported flat revenue but beat EPS estimates. ScanSource had the largest analyst estimate beat. TD SYNNEX reported $19.57B revenue, up 31% YoY, and beat EPS estimates and guidance.

$PLUSMed

Plus500 increases buybacks as US growth continues

Plus500 said it will increase shareholder returns via buybacks alongside its half-year results. The company reported double-digit revenue growth year over year and Ebitda up 1% to $188mn. It attributed a lower Ebitda margin (45% to 41%) to higher marketing spend to attract new customers, while expanding in US futures.

$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.